Progressive Fibrosis: A Progesterone- and KLF11-Mediated Sexually Dimorphic Female Response

Endocrinology. 2017 Oct 1;158(10):3605-3619. doi: 10.1210/en.2017-00171.

Abstract

Progressive scarring is ubiquitous postoperatively and in an array of chronic systemic diseases. Recent studies indicate that such scarring has a high female propensity; females are also almost exclusively affected by endometriosis, a common sex steroid-dependent fibrotic disease. Endometriosis-related fibrosis is regulated epigenetically through transcription factor Krüppel-like factor 11 (KLF11). In response to surgical induction of endometriosis, Klf11-/- female mice develop significant fibrosis in contrast to wild-type mice. We therefore hypothesized that female fibrotic predilection was mediated by differential sex steroid regulation of KLF11/collagen 1a1 signaling and investigated the fibrotic response in wild-type and Klf11-/- male and female animals using a sterile peritonitis model. Fibrosis selectively developed in Klf11-/- females. Fibrosis in these animals was almost completely abrogated by ovariectomy. Ovariectomized animals were selectively supplemented with estradiol, medroxyprogesterone acetate (MPA), or dihydrotestosterone; fibrosis was only observed in mice exposed to MPA. Fibrosis therefore selectively developed in Klf11-/- female mice in response to physiological or pharmacological progesterone. The fibrotic response in these animals was also mitigated in response to antiprogestin therapy. Profibrotic gene expression was activated in a primary human peritoneal cell line in response to KLF11 short hairpin RNA and MPA but not estradiol. KLF11/collagen 1a1 signaling previously shown to be linked to fibrosis was thus selectively dysregulated in MPA-treated cells. Our in vivo and in vitro findings in an animal model and human cells, respectively, suggest that progressive fibrotic scarring is a sexually dimorphic response irrespective of etiology; moreover, it is responsive to novel, individualized therapeutic intervention.

MeSH terms

  • Androgens / pharmacology
  • Animals
  • Apoptosis Regulatory Proteins
  • Cell Cycle Proteins / genetics
  • Cell Line
  • Collagen Type I / metabolism
  • Collagen Type I, alpha 1 Chain
  • DNA-Binding Proteins / genetics*
  • Dihydrotestosterone / pharmacology
  • Estradiol / pharmacology
  • Estrogens / pharmacology
  • Female
  • Fibrosis / genetics*
  • Fibrosis / metabolism
  • Gene Expression
  • Humans
  • In Vitro Techniques
  • Male
  • Medroxyprogesterone Acetate / pharmacology
  • Mice
  • Mice, Knockout
  • Ovariectomy
  • Peritoneum / cytology
  • Peritoneum / drug effects
  • Peritoneum / pathology*
  • Peritonitis
  • Progesterone / metabolism*
  • Progestins / pharmacology
  • RNA, Small Interfering
  • Repressor Proteins / genetics
  • Sex Factors
  • Transcription Factors / genetics*

Substances

  • Androgens
  • Apoptosis Regulatory Proteins
  • Cell Cycle Proteins
  • Collagen Type I
  • Collagen Type I, alpha 1 Chain
  • DNA-Binding Proteins
  • Estrogens
  • KLF11 protein, human
  • KLF11 protein, mouse
  • Progestins
  • RNA, Small Interfering
  • Repressor Proteins
  • Transcription Factors
  • Dihydrotestosterone
  • Progesterone
  • Estradiol
  • Medroxyprogesterone Acetate